In the current environment, nascent biotech companies can raise funding from a variety of sources. This panel examines trends among the most common funding sources between startup and pre-IPO stage. Where will the focus of independent venture capital firms be? How will strategic venture capital firms balance ‘traditional’ investments versus build-to-buy in independent companies? Will grant and contract funding remain a sustainable source of capital? What will the effects of the currently COVID focused funding be on other areas, such as cancer? Join us for a discussion on how startups should consider these questions and how best to move forward in a post-COVID world.